Management of women with a family history of breast cancer

International Journal of Clinical Practice

Volumn 53, Issue 3, 1999, Pages 192-196

  Curry, P ^a   Fentiman, I S ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

BREAST CANCER; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MASTECTOMY; ONCOGENE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ATAXIA TELANGIECTASIA; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; LI-FRAUMENI SYNDROME; MASTECTOMY; PEDIGREE; TAMOXIFEN;

EID: 0032929457     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Office of Population Censuses and Surveys. 1989 cancer registrations. London: HMSO, 1989.
2. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for the autosomal dominant transmission in high risk families. Proc Natl Acad Sci USA, 1988: 85: 3044-3048.
3. Iselius L, Slack J, Little M, Morton ME. Genetic epidemiology of breast cancer in Britain. Ann Hum Genet 1991; 55: 151-159.
4. Lloyd KM, Dennis M. Cowden's disease: a new symptom complex with multiple system involvement. Ann Intern Med 1963; 58: 136-142.
5. Chen P, Farrell A, Hobson K et al. Comparative study of radiation-induced G2 phase delay and chromatin damage in families with ataxia telangiectasia. Cancer Genet Cytogenet 1994; 76: 43-46.
6. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected with ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836.
7. Easton D. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994; 66: s177-s182.
8. Norman A, Withers HR. Mammography screening for A-T heterozygotes. In: Gatti RA, Painter RB, Eds. Ataxia-telangiectasia. Berlin: Springer 1993: 137-140.
9. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71: 747-752.
10. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233-1238.
11. Zelada-Hedman M, Borresen-dale A-L, Clarpo A et al. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 1997; 75: 1201-1204.
12. Hall JM, Lee MK, Morrow JK et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689.
13. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science 1994; 266: 66-71.
14. Easton DF, Ford D, Bishop DT and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 carriers. Am J Hum Genet 1995; 56: 265-271.
15. Smith SA, Easton DF, Evans DGR, Ponder BAJ. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 1992; 2: 128-131.
16. Couch FJ, De Shano ML, Blackwood MA et al. BRCA1 mutations in women attending clinics that evaluate risk of breast cancer. N Engl J Med 1997; 336: 1409-1415.
17. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457-1462.
18. Fitzgerald MG, Macdonald D, Krainer M et al. Germ-line mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334: 137-142.
19. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
20. Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA1 mutation carriers. Lancet 1994; 343: 692-695.
21. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 1995; 11: 198-200.
22. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
23. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. implications for risk projection. Cancer 1994; 73: 643-651.
24. McGuigan KA, Ganz PA, Breant C. Agreement between breast cancer risk estimation methods. J Natl Cancer Inst 1996; 88: 1315-1317.
25. Vasen HFA, Beex LVAM, Cleton FJ et al. Clinical heterogeneity of hereditary breast cancer and its impact on screening protocols: the Dutch experience on 24 families under surveillance. Eur J Cancer 1993; 29A: 1111-1114.
26. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet 1992; 339: 1-15, 71-84.
27. National Cancer Institute. Breast cancer prevention trial shows major benefit, some risk [web site news release]
28. Josefson D. Breast cancer trial stopped early. BMJ 1998; 316: 1187.
29. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprotection trial. Lancet 1998; 352: 98-101.
30. Karp SE, Tonin PN, Begin LR et al. Influence of BRCA1 mutations on nuclear grade and oestrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997; 80: 435-444.
31. Veronesi U, Maisonneuve P et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97.
32. Hartmann L, Jenkins R, Schaid D, Yang P. Prophylactic mastectomy; preliminary retrospective cohort analysis. Proc Am Assoc Cancer Res 1997; 38: 1123.
33. Wong JH, Jackson CF et al. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with DMBA induced breast cancer. Surgery 1986; 99: 67-71.
34. Schrag D, Kuntz DM, Garber JE, Weeks JC. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 1997; 336: 1465-1471.
35. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
36. Fentiman IS. Prophylactic mastectomy: deliverance or delusion? BMJ 1998; 317: 1402-1403.
37. Russo J, Russo IH. Hormonally induced differentiation: a novel approach to breast cancer prevention. J Cell Biochem 1995; 22: 58-64.
38. Taylor-Papadimitriou J, Gendler SJ. Structure, biology and possible clinical applications of carcinoma associated mucins. Int J Oncol 1992; 1: 9-16.
39. Borg A, Ferno M et al. C-erb2 amplification in breast cancer with a high risk of proliferation. Oncogene 1991; 6: 137-143.
40. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
41. Bischoff JR, Kim D, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 1996; 274: 373-376.